Patents by Inventor Ene Ustav
Ene Ustav has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11000529Abstract: Methods for treating high risk HPV infection by inhibiting one or more phases of HPV replication cycle with antiviral compounds are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.Type: GrantFiled: September 12, 2019Date of Patent: May 11, 2021Assignee: Icosagen Cell Factory OÜInventors: Mart Ustav, Sr., Ene Ustav, Andres Männik, Mart Toots, Andres Tover
-
Patent number: 10954545Abstract: A U2OS-based model system using luciferase reporters to monitor the genome replication of alpha and beta HPVs is provided. A modified U2OS cell line is disclosed that expresses Firefly luciferase to measure toxicity of the screened compounds. In addition, provided are HPV18, HPV 16 and HPV5 marker genomes that express Renilla luciferase under the control of viral promoters used to measure changes in the viral copy number. This ready-to-use model system is capable of being used in high-throughput screens to identify compounds inhibiting initial amplification and stable maintenance as well as vegetative phase of various HPV subtypes.Type: GrantFiled: April 11, 2016Date of Patent: March 23, 2021Assignee: Icosagen Cell Factory OÜInventors: Mart Ustav, Ene Ustav, Andres Männik, Mart Toots, Mart Ustav, Jr., Andres Tover
-
Publication number: 20200046730Abstract: Methods for treating high risk HPV infection by inhibiting one or more phases of HPV replication cycle with antiviral compounds are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.Type: ApplicationFiled: September 12, 2019Publication date: February 13, 2020Applicant: Icosagen Cell Factory OÜInventors: Mart USTAV, SR., Ene USTAV, Andres MÄNNIK, Mart TOOTS, Andres TOVER
-
Patent number: 10543218Abstract: Novel antiviral compounds for inhibiting one or more phases of HPV replication cycle are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.Type: GrantFiled: May 11, 2016Date of Patent: January 28, 2020Assignee: Icosagen Cell Factory OÜInventors: Mart Ustav, Sr., Ene Ustav, Andres Männik, Mart Toots, Andres Tover
-
Publication number: 20180155756Abstract: A U2OS-based model system using luciferase reporters to monitor the genome replication of alpha and beta HPVs is provided. A modified U2OS cell line is disclosed that expresses Firefly luciferase to measure toxicity of the screened compounds. In addition, provided are HPV18, HPV 16 and HPV5 marker genomes that express Renilla luciferase under the control of viral promoters used to measure changes in the viral copy number. This ready-to-use model system is capable of being used in high-throughput screens to identify compounds inhibiting initial amplification and stable maintenance as well as vegetative phase of various HPV subtypes.Type: ApplicationFiled: April 11, 2016Publication date: June 7, 2018Applicant: Icosagen Cell Factory OÜInventors: Mart USTAV, Ene USTAV, Andres MÄNNIK, Mart TOOTS, Mart USTAV, JR., Andres TOVER
-
Publication number: 20180133228Abstract: Novel antiviral compounds for inhibiting one or more phases of HPV replication cycle are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.Type: ApplicationFiled: May 11, 2016Publication date: May 17, 2018Applicant: Icosagen Cell Factory OÜInventors: Mart Ustav, Sr., Ene Ustav, Andres Männik, Mart Toots, Andres Tover
-
Patent number: 9725486Abstract: A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells.Type: GrantFiled: January 13, 2014Date of Patent: August 8, 2017Assignee: Fit Biotech OYInventors: Kai Krohn, Vesna Blazevic, Marja Tähtinen, Mart Ustav, Urve Toots, Andres Männik, Annamari Ranki, Ene Ustav
-
Publication number: 20140234361Abstract: A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells.Type: ApplicationFiled: January 13, 2014Publication date: August 21, 2014Applicant: FIT Biotech OyInventors: Kai KROHN, Vesna Blazevic, Marja Tähtinen, Mart Ustav, Urve Toots, Andres Männik, Annamari Ranki, Ene Ustav
-
Publication number: 20130236958Abstract: This disclosure shows that the EBV FR-element comprised of EBNA1 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT).Type: ApplicationFiled: January 23, 2013Publication date: September 12, 2013Applicant: ICOSAGEN CELL FACTORY OUInventors: Toomas SILLA, Ingrid TAGEN, Jelizaveta GEIMANEN, Kadri JANIKSON, Aare ABROI, Ene USTAV, Mart USTAV, Tiiu MANDEL, Urve TOOTS, Andres TOVER, Anne KALLING, Radi TEGOVA
-
Patent number: 8377653Abstract: This disclosure shows that the EBV FR-element comprised of EBNA1 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT).Type: GrantFiled: July 7, 2010Date of Patent: February 19, 2013Assignee: Icosagen Cell Factory OüInventors: Toomas Silla, Ingrid Tagen, Anne Kalling, Radi Tegova, Mart Ustav, Tiiu Mandel, Urve Toots, Andres Tover, Aare Abroi, Ene Ustav, Jelizaveta Geimanen, Kadri Janikson
-
Publication number: 20110076760Abstract: This disclosure shows that the EBV FR-element comprised of EBNA1 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT).Type: ApplicationFiled: July 7, 2010Publication date: March 31, 2011Applicant: Icosagen S.A.Inventors: Toomas Silla, Ingrid Tagen, Anne Kalling, Radi Tegova, Mart Ustav, Tiiu Mandel, Urve Toots, Andres Tover, Aare Abroi, Ene Ustav, Jelizaveta Geimanen, Kadri Janikson
-
Publication number: 20100279416Abstract: The invention relates to a method for introducing changes into a eukaryotic genome in vivo wherein the HPV genome, which comprises HPV replication origin sequence, is used together with HPV early proteins in order to achieve DNA replication in vivo. There is also disclosed a kit for in vivo amplification, excision, translocation and/or inversion of a DNA sequence, which comprises a vector carrying HPV genome or a part of HPV genome including HPV replication origin sequence, and expression vector or vectors encoding HPV early proteins.Type: ApplicationFiled: March 27, 2008Publication date: November 4, 2010Inventors: Mart Ustav, Ene Ustav, Meelis Kadaja, Alina Sumerina
-
Patent number: 7790446Abstract: This disclosure shows that the BPV-1 E2 protein-dependent minichromosome maintenance element (MME) comprised of E2 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT). MME dependent plasmids are lost with the frequency of 6% per generation. Significantly long stable maintenance replication can also be provided without selection pressure. We also demonstrate that PyV core origin maintenance function/replication activation could be provided by Epstein-Barr virus Family of repeats and EBNA1 protein. The maintenance of the Polyomavirus core origin plasmid was characterized by 13% loss of the plasmid during one cell generation in the case of EBV FR harboring plasmids.Type: GrantFiled: February 10, 2006Date of Patent: September 7, 2010Assignee: Kosagen Cell Factory OüInventors: Toomas Silla, Ingrid Tagen, Jelizaveta Geimanen, Kadri Janikson, Aare Abroi, Ene Ustav, Mart Ustav, Tiiu Mandel
-
Publication number: 20090252707Abstract: A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells.Type: ApplicationFiled: January 27, 2009Publication date: October 8, 2009Applicant: FIT BIOTECH OYInventors: KAI KROHN, VESNA BLAZEVIC, MARJA TAHTINEN, MART USTAV, URVE TOOTS, ANDRES MANNIK, ANNAMARI RANKI, ENE USTAV
-
Patent number: 7510718Abstract: The present invention relates to novel vectors, to DNA vaccines and gene therapeutics containing the vectors, to methods for the preparation of the vectors and DNA vaccines and gene therapeutics containing the vectors, and to therapeutic uses of the vectors. The novel vectors comprise (a) an expression cassette of a gene of a nuclear-anchoring protein, which contains (i) a DNA binding domain capable of binding to a specific DNA sequence and (ii) a functional domain capable of binding to a nuclear component and (b) a multimerized DNA sequence forming a binding site for the anchoring protein, and optionally (c) one or more expression cassettes of a DNA sequence of interest. The vectors lack a papilloma virus origin of replication.Type: GrantFiled: May 3, 2002Date of Patent: March 31, 2009Assignee: Fit Biotech Oyj PLCInventors: Kai Krohn, Vesna Blazevic, Marja Tahtinen, Mart Ustav, Urve Toots, Andres Mannik, Annamari Ranki, Ene Ustav
-
Patent number: 7498314Abstract: The present invention relates to novel vectors, to DNA vaccines and gene therapeutics containing said vectors, to methods for the preparation of the vectors and DNA vaccines and gene therapeutics, and to therapeutic uses of said vectors. More specifically, the present invention relates to novel vectors comprising an expression cassette of a gene of a nuclear-anchoring protein, which contains a DNA binding domain capable of binding to a specific DNA sequence and a functional domain capable of binding to a nuclear component and a multimerized DNA sequence forming a binding site for the nuclear-anchoring protein, and optionally an expression cassette of a gene, genes or a DNA sequence or DNA sequences of interest. The present invention further relates to DNA vaccines and gene therapeutics containing the novel vectors, to methods for the preparation of the novel vectors and the DNA vaccines and gene therapeutics.Type: GrantFiled: May 3, 2002Date of Patent: March 3, 2009Assignee: Fit Biotech Oyj PLCInventors: Kai Krohn, Vesna Blazevic, Marja Tähtinen, Mart Ustav, Urve Toots, Andres Männik, Annamari Ranki, Ene Ustav
-
Publication number: 20060183230Abstract: This disclosure shows that the BPV-1 E2 protein-dependent minichromosome maintenance element (MME) comprised of E2 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT). MME dependent plasmids are lost with the frequency of 6% per generation. Significantly long stable maintenance replication can also be provided without selection pressure. We also demonstrate that PyV core origin maintenance function/replication activation could be provided by Epstein-Barr virus Family of repeats and EBNA1 protein. The maintenance of the Polyomavirus core origin plasmid was characterized by 13% loss of the plasmid during one cell generation in the case of EBV FR harboring plasmids.Type: ApplicationFiled: February 10, 2006Publication date: August 17, 2006Inventors: Toomas Silla, Ingrid Tagen, Jelizaveta Geimanen, Kadri Janikson, Aare Abroi, Ene Ustav, Mart Ustav, Tiiu Mandel
-
Publication number: 20050026137Abstract: The present invention relates to novel vectors, to DNA vaccines and gene therapeutics containing said vectors, to methods for the preparation of the vectors and DNA vaccines and gene therapeutics containing the vectors, and to therapeutic uses of said vectors. More specifically, the present invention relates to novel vectors comprising (a) an expression cassette of a gene of a nuclear-anchoring protein, which contains (i) a DNA binding domain capable of binding to a specific DNA sequence and (ii) a functional domain capable of binding to a nuclear component and (b) a multimerized DNA sequence forming a binding site for the anchoring protein, and optionally (c) one or more expression cassettes of a DNA sequence of interest. In particular the invention relates to vectors that lack a papilloma virus origin of replication. The nuclear-anchoring protein might be the E2 protein of Bovine Papilloma Virus type 1 or Epstein-Barr Virus Nuclear Antigen 1.Type: ApplicationFiled: May 3, 2002Publication date: February 3, 2005Inventors: Kai Krohn, Vesna Blazevic, Marja Tahtinen, Mart Ustav, Urve Toots, Andres Mannjk, Annamari Ranki, Ene Ustav
-
Publication number: 20030129169Abstract: The present invention relates to novel vectors, to DNA vaccines and gene therapeutics containing said vectors, to methods for the preparation of the vectors and DNA vaccines and gene therapeutics, and to therapeutic uses of said vectors. More specifically, the present invention relates to novel vectors comprising an expression cassette of a gene of a nuclear-anchoring protein, which contains a DNA binding domain capable of binding to a specific DNA sequence and a functional domain capable of binding to a nuclear component and a multimerized DNA sequence forming a binding site for the nuclear-anchoring protein, and optionally an expression cassette of a gene, genes or a DNA sequence or DNA sequences of interest. The present invention further relates to DNA vaccines and gene therapeutics containing the novel vectors, to methods for the preparation of the novel vectors and the DNA vaccines and gene therapeutics containing the novel vectors, and to the use the vectors in therapy.Type: ApplicationFiled: May 3, 2002Publication date: July 10, 2003Inventors: Kai Krohn, Vesna Blazevic, Marja Tahtinen, Mart Ustav, Urve Toots, Andres Mannik, Annamari Ranki, Ene Ustav